Cover image of the article: Burden of the central nervous system malignancies in Iran 2003

Image Credit:Int J Cancer Manag

Burden of the central nervous system malignancies in Iran 2003

Authors

AR. Zali1, F. Abolhassani2, Maryam Khayamzade3,*, M. Moradi Lake4, A. Jamali4, R. Salmanian5, M. Naghavi6, HR. Mirzaei7, A. Kazemian8, ME. Akbari9
1Associated Profurgery Shahid Beheshti Medical Universityessor of Neuros, Tehran, Iran
2Assistant Professor of Endocrine and metabolism Research Center, Tehran Medical University, Tehran, Iran
3Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Community Medicine Specialist Assistant Professor of Iran Medical University, Tehran, Iran
5Resident of Anestisiology Iran Medical University, Tehran, Iran
6Epidemiologist (MD-PhD) Researcher- Ministry Of health and Medical Education, Iran
7Radio therapy oncology specialist - Cancer Research Center, Assistant Professor of Shahid Beheshti Medical University, Tehran, Iran
8Radio therapy oncology specialist, Assistant Professor of Tehran Medical University, Tehran, Iran
9Professor of Surgery- Cancer Research Center, Shahid Beheshti Medical University, Tehran, Iran
*Corresponding Author: Corresponding author: Maryam Khayamzade, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tel: +98-2122748001-2, Fax: +98-2122748001-2, E-mail: Email: khayamzadeh@yahoo.com

International Journal of Cancer Management:Vol. 1, issue 1; e80377
Published online:Jan 31, 2008
Article type:Research Article
Received:Jan 31, 2008
Accepted:Jan 31, 2008
How to Cite:Zali A, Abolhassani F, Khayamzade M, Moradi Lake M, Jamali A, et al. Burden of the central nervous system malignancies in Iran 2003. Int J Cancer Manag. 2008;1(1):e80377. doi:

Abstract

Objective: The policy makers and social managers need some criteria for building up the appropriate health status of the community and observe the equity and equality on it. They have to know the burden of diseases as a main determining factor for decision making, planning and programming. Disability adjusted life years (DALYs) is a criteria which shows the wasted life time due to early death and also wasted time due to disease morbidity and disability. Central nervous system malignancies are important especially in children and estimating the burden of these malignancies in Iran will enable the health policy makers to share the community sources, as appropriate.

Material and Methods: The estimation of burden of disease and risk factors was a national study that began on 2003 by the ministry of Health and Medical education (MOH&ME) after establishing cancer registry in the country. Here by we discussed about the burden of CNS malignancies as a part of this study. This study was performed by a special modeling and new software.

Results: Due to wasted life time of early death and morbidity, CNS malignancies are the third malignancy in Iran. Year waste in Iranian Population is 0.69 in each 1000 person.

Highlights

Fulltext

Full text is available in PDF.

Copyright

© 2008, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

30
Apr
2018
Epidemiology of Nervous System Tumors According to WHO 2007 Classification: A Report of 1,164 Cases from a Single Hospital

Epidemiology of Nervous System Tumors According to WHO 2007 Classification: A Report of 1,164 Cases from a Single Hospital

Narges Jafarzadeh,
Arash Faal,
Azra Izanloo,
Farid Farrokhi,
Reza Ziaolhagh,
Hamid Reza Hashemian
,et al.

Jafarzadeh N, Faal A, Izanloo A, Farrokhi F, Ziaolhagh R, et al. Epidemiology of Nervous System Tumors According to WHO 2007 Classification: A Report of 1,164 Cases from a Single Hospital. Int J Cancer Manag. 2018;11(4):e11462. doi: https://doi.org/10.5812/ijcm.11462

3
Jul
2010
Cancer Incidence in South East of Iran: Results of a Population-Based Cancer Registry

Cancer Incidence in South East of Iran: Results of a Population-Based Cancer Registry

MA Mashhadi

Mashhadi M. Cancer Incidence in South East of Iran: Results of a Population-Based Cancer Registry. Shiraz E-Med J. 2010;11(3):20401. doi:

2
Aug
2023
Incidence, mortality and DALY trends in neurological disorders in children aged 0-14 years in Iran: Estimates from the Burden of Disease Study of the year 1990- 2019

Incidence, mortality and DALY trends in neurological disorders in children aged 0-14 years in Iran: Estimates from the Burden of Disease Study of the year 1990- 2019

Jamile Shahverdi,
Zaher Khazaei,
Afsaneh Badrizadeh,
Sajjad Rahimi Pordanjani,
Elham Goudarzi

Shahverdi J, Khazaei Z, Badrizadeh A, Rahimi Pordanjani S, Goudarzi E. Incidence, mortality and DALY trends in neurological disorders in children aged 0-14 years in Iran: Estimates from the Burden of Disease Study of the year 1990- 2019. koomesh. 2023;25(2):e152818. doi:

1
Jul
2019
National Cancer Mortality-to-Incidence Ratio (MIR) in Iran (2005 - 2014)

National Cancer Mortality-to-Incidence Ratio (MIR) in Iran (2005 - 2014)

Atieh Akbari,
Maryam Khayamzadeh,
Reza Salmanian,
Ali Ghanbari Motlagh,
Gholamreza Roshandel,
Maryam Nouri
,et al.

Akbari A, Khayamzadeh M, Salmanian R, Ghanbari Motlagh A, Roshandel G, et al. National Cancer Mortality-to-Incidence Ratio (MIR) in Iran (2005 - 2014). Int J Cancer Manag. 2019;12(6):e94145. doi: https://doi.org/10.5812/ijcm.94145

31
Jul
2022
Mortality Rates and Years of Life Lost Due to Cancer in Iran: Analysis of Data from the National Death Registration System, 2016

Mortality Rates and Years of Life Lost Due to Cancer in Iran: Analysis of Data from the National Death Registration System, 2016

Neda Izadi,
Koorosh Etemad,
Parisa Mohseni,
Ardeshir Khosravi,
Mohammad Esmaeil Akbari

Izadi N, Etemad K, Mohseni P, Khosravi A, Akbari ME. Mortality Rates and Years of Life Lost Due to Cancer in Iran: Analysis of Data from the National Death Registration System, 2016. Int J Cancer Manag. 2022;15(6):e123633. doi: https://doi.org/10.5812/ijcm-123633

More by these authors

F. AbolhassaniPubMedScholar
Maryam KhayamzadePubMedScholar
M. Moradi LakePubMedScholar
A. JamaliPubMedScholar
R. SalmanianPubMedScholar
M. NaghaviPubMedScholar
HR. MirzaeiPubMedScholar
A. KazemianPubMedScholar
ME. AkbariPubMedScholar
Share
Cited by
Metrics